Nausea and vomiting associated with GLP-1 agonists The majority of people who start using a GLP-1 for obesity will discontinue it in the first year, with 45% to 65% citing GI side effects as the reason for discontinuing therapy
Bays , MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM, medical director at Louisville Metabolic and Atherosclerosis Research Center, Monroe Biomedical Research and clinical associate professor at University of Louisville School of Medicine, told Healio
Nomost patients report that side effects are worst during the first injection, mild during the second, and nearly absent by the fourth or fifth dose
The pathophysiological mechanisms that contribute to these symptoms remain unclear
The portal is your hub for real-time information